• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Biosimilar Filing Could Be A Game Changer For Alvotech Stock (ALVO)

    Simply Wall St·10/20/2026 20:27:42
    Listen to the news
    • Alvotech and Advanz Pharma reported that they submitted a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg, as a line extension to the existing Mynzepli authorization. This marks the first worldwide filing for this higher strength aflibercept formulation.
    • The rapid shift of Eylea sales toward the 8 mg dose, which accounted for about 57% of combined global Eylea 2 mg and 8 mg sales by value in Q2 2026, positions Alvotech’s AVT29 filing within a large and dosing-efficient segment of the retinal disease market.
    • We will now look at how Alvotech's investment narrative could be reshaped by the first European filing for an Eylea 8 mg biosimilar.

    Scan beyond Alvotech and see how other biosimilar and healthcare manufacturers are positioning for the next leg of demand using our curated list of 33 healthcare AI stocks.

    Alvotech Investment Narrative Recap

    To own Alvotech, you need to believe the biosimilar model can scale from a pipeline story into a diversified commercial engine, even with heavy reliance on partners and milestone-based revenue. The AVT29 filing fits that belief because it targets a large, dosing-efficient part of the eye disease market, but it likely does not overtake near term approval and launch milestones for other key products as the primary catalyst.

    The biggest operational risk remains timing. Regulatory delays or slower than expected uptake for launched biosimilars would land on a cost base that already carries high debt and increased R&D and acquisition spending. AVT29 does not fully change that liquidity picture in the short run, even if it strengthens the medium term retinal portfolio story.

    The long term manufacturing agreement with LOTTE Biologics ties directly into the AVT29 story. If Alvotech wants to support wider adoption across multiple antibody biosimilars, it needs reliable, scalable drug substance supply. This partnership adds US based capacity with an FDA inspected site that recently completed an unannounced review with no observations.

    That extra capacity matters for catalysts and risk. Strong execution on technology transfer and qualification would give Alvotech more flexibility to meet potential demand surges from new approvals while reducing single site dependency. Any issues in bringing LOTTE’s Syracuse facility fully online or in aligning regulatory approvals with production plans could compound the existing exposure to lumpy milestone income and high fixed costs.

    Alvotech's current revenue outlook assumes 25.4% yearly top line growth, with earnings today at a loss of $179.6 million and consensus earnings of $223.1 million by 2029. That implies revenues of $976.3 million and an earnings swing of about $402.7 million by the 2029 forecast year.

    Uncover why Alvotech's fair value indicates a 35% potential upside to its current price that may not last much longer.

    NasdaqGM:ALVO 1-Year Stock Price Chart
    NasdaqGM:ALVO 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view focuses squarely on regulatory timing risk for Alvotech. The most cautious analysts, who were only penciling in about 20.5% yearly revenue growth and earnings of roughly $82.7 million by 2029 before this AVT29 filing, see approval slippage as the core issue. Use that gap to assess how your own expectations might shift as this news is absorbed.

    Explore 4 other Alvotech fair value estimates, including one that suggests there may be as much as 20% downside from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Alvotech?

    Once you have a view on Alvotech, it can help to widen the lens and compare it with other opportunities on the Simply Wall St Screener.